Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.


Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

Saturday, May 06, 2006 - Sunday, May 07, 2006
Holiday Inn Express, Philadelphia, PA

The cutaneous T-cell lymphomas represent a group of rare, non-Hodgkin’s lymphomas that are primarily localized to skin or have overt skin manifestations along with internal involvement. They are represented by mycosis fungoides, Sezary syndrome, CD30-positive skin lymphomas, and other variants. No treatment has been shown to be curative. Although most individuals have indolent disease, those with advanced disease obtain only partial, short-term benefit from chemotherapy and often die of disease or its most severe complication—infection and sepsis. There are several reasons to believe that cutaneous T-cell lymphomas may respond to or benefit from immunotherapy or immunoregulatory therapy. The goals of this conference were to educate the audience about new immuno-based therapies and strategies for CTCL and to bring together researchers and clinicians who treat CTCL to formulate strategies for clinical trials based on information disseminated in the meetings.

Dr. Sam T. Hwang (301) 496-8724

Co-funding Institute(s):
National Cancer Institute

From the National Center for Advancing Translational Sciences

From the National Institutes of Health

Connect with ORDR

See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.